Solvias Opens Center of Excellence for Biologics and Cell & Gene Therapy in Research Triangle Park
MORRISVILLE, N.C., Jan. 27, 2025 /PRNewswire/ -- Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today the opening of its cutting-edge Center of Excellence for Biologics and Cell and Gene Therapy in the heart of Research Triangle Park (RTP), North Carolina. The new facility expands Solvias' global network of centers and reinforces its commitment to advancing transformative therapies for cancer and rare diseases.
Spanning 50,000 square feet, the new center is Solvias' flagship North American site for large molecule analytical services designed to accelerate the development and commercialization of innovative biologics. The facility will bring approximately 200 new jobs to the Raleigh-Durham area over the next three years and is being rolled out in two phases:
Phase 1: A 20,000-square-foot space for cGMP release testing—featuring cell-based potency and molecular assays—operational immediately.
Phase 2: An additional 30,000 square feet expected to open in July 2025, offering expanded capabilities for stability testing and advanced biophysical characterization.
Equipped with state-of-the art analytical instrumentation, laboratory automation, and advanced digital management systems, the new center offers comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biologics, from preclinical stages to commercial release.
'This Center of Excellence in RTP is a milestone in Solvias' global growth journey,' said Archie Cullen, Chief Executive Officer of Solvias. 'Combining our team's expertise with advanced technology, we aim to set a new benchmark for delivering high-quality, reliable analytical support. It's an honor to partner with our clients in bringing groundbreaking therapies to patients worldwide.'
'We are focused on helping our clients succeed with our analytical expertise. We are hiring the best possible talent to be technical partners for our clients, helping them bring therapies to market faster and more efficiently. With this investment, we are committed to be an integral part of the US biopharma innovation ecosystem,' said Ilya Koltover, Chief Commercial Officer of Solvias.
Solvias' new center expands its global footprint to six centers of excellence and marks the company's second site in North America. For more information on Solvias' new Center of Excellence in RTP, visit solvias.com.
About Solvias
Solvias is a global provider of chemistry, manufacturing, and control (CMC) analytics to the life sciences industry. Its expert team combines decades of experience with regulatory expertise across small molecules, biologics, and cell and gene therapies. Solvias offers end-to-end solutions from raw material testing to drug product release and API development for small molecules. Headquartered near Basel, Switzerland, Solvias operates six global Centers of Excellence, all adhering to the highest ISO, GMP, GLP, and FDA standards. For more information, visit solvias.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
CHAI AI: Expands GPU Cluster to Reach 1.4 exaFLOPS in Compute
PALO ALTO, Calif., June 11, 2025 /PRNewswire/ -- CHAI, a leader in social AI, is betting big on compute—announcing aggressive infrastructure scaling to fuel its next-generation AI models. Since 2023, the company has made strategic investments in high-performance computing clusters that now compete with leading AI labs and startups. Investing in Next-Gen AI Models In 2025, CHAI projects to allocate $20M to further expand its compute capacity—a bold move that solidifies its competitive edge in AI research and product innovation. This strategic investment reflects broader industry trends where firms are racing to secure computing resources amid growing demand for AI capabilities. CHAI's in-house kCluster now delivers 1.4 exaFLOPs of computing power by utilizing thousands of cutting-edge GPUs. This infrastructure outpaces most AI startups in compute capability and surpasses academic benchmarks, offering nearly 10x the power of Stanford's Sherlock HPC Cluster. Leveraging this massive infrastructure advantage, CHAI accelerates cutting-edge AI research and serves over 51,000 LLMs to users worldwide, enabling richer interactions and deeper personalization. Was CHAI the first AI Platform? CHAI was the first consumer AI product to reach 1 million users, leveraging the open-sourced LLM GPT-J, before ChatGPT or Llama. What is CHAI? CHAI is a social AI platform where users can create their own AI. Since its launch three years ago, CHAI has experienced significant growth, particularly among Gen Z users. Now, to support further growth and wider adoption, CHAI has redesigned its brand. Can you use CHAI AI in a browser? As of March 2025, no. CHAI is focused on delivering the most engaging social AI experience by hiring talented engineers to refine its app. While there are currently no plans for a web app, this may change in the future. Is CHAI AI safe? CHAI has implemented a range of safety features that allow users to engage in dynamic chats while encouraging them to stay within established guidelines. By building better AI, CHAI aims to enhance user value and experience. What makes CHAI special? CHAI is designed to be the most engaging social AI, delivering highly entertaining conversations. Many users rely on it to craft interactive stories and immersive experiences. Why do people love CHAI? CHAI employs advanced AI techniques to increase the entertainment value of its bots. Users chat with AI to write interactive novels and have engaging conversations, supported by a variety of genres that appeal to avid novel readers. Sometimes regarded as the best free AI chatbot, CHAI is paving its way to widespread adoption of conversational social AI for entertainment. Who is the founder? William Beauchamp is a 2x founder, first started building CHAI with his sister in Cambridge UK in 2020. After building the first AI chat platform they relocated to Palo Alto. Are they hiring? CHAI is a rapidly growing company that is known for paying very high salaries with an intense culture focused on delivering results and iterating quickly. Apply on CHAI's website. View original content to download multimedia: SOURCE Chai Research Corp Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
Yahoo
an hour ago
- Yahoo
Vantage Debuts at Wealth Expo Perú 2025 Showcasing Industry Expertise
PORT VILA, Vanuatu, June 12, 2025 /PRNewswire/ -- Vantage Markets is pleased to announce its inaugural participation in Wealth Expo Perú 2025, a notable financial industry events in the region. The event will take place at the prestigious Westin Hotel in San Isidro, the heart of Lima's financial district, bringing together traders, investors, fintech experts, and financial service providers for a full day of knowledge-sharing, networking, and industry discussion. Marking its first-ever appearance at the Peruvian edition of Wealth Expo, Vantage will present its innovative solutions and engage with attendees from the trading and affiliate community. The company's participation will include three speaking sessions led by members of its expert team: Rodrigo Martínez, Team Lead of Business Development, will deliver a keynote on "Vantage: Smart Copy Trading Within Everyone's Reach" – a deep dive into Vantage's intuitive and accessible copy trading platform. He will also join other industry experts on a panel discussing key trends, challenges, and developments within the evolving financial ecosystem in Peru and the wider region. In the workshop track, Julio Vásquez, Business Development Manager, will share insights during his talk: "How to Turn Your Trading and Community into a Passive Income Machine". To kick off the summit in style, Vantage will sponsor an exclusive cocktail reception the evening before the main event. This private gathering will welcome attendees with warm hospitality and an opportunity to connect with the Vantage team in a relaxed setting. Marc Despallieres, CEO of Vantage Markets, shared: "We are pleased to participate in Wealth Expo Perú, an important event within Latin American's growing financial landscape. The region continues to show significant interest in trading and innovation, and we look forward to engaging with industry partners and stakeholders. Through education, technology, and trust, Vantage remains committed to supporting the evolving financial ecosystem." Vantage's growing presence reflects its ongoing commitment to making financial markets more accessible, transparent, and rewarding for traders of all experience levels. For more details on Vantage's initiatives and events, visit Vantage Markets. About Vantage Vantage Markets (or Vantage) is a multi-asset CFD broker offering clients access to a nimble and powerful service for trading Contracts for Difference (CFDs) products, including Forex, Commodities, Indices, Shares, ETFs, and Bonds. With over 15 years of market experience, Vantage transcends the role of broker, providing a reliable trading platform, an award-winning mobile trading app, and a user-friendly trading platform that provide clients access to trading opportunities. trade smarter @vantage RISK WARNING: CFDs are complex instruments and carry a high risk of losing money rapidly due to leverage. Ensure you understand the risks before trading. Disclaimer: This article is provided for informational purposes only and does not constitute financial advice, an offer, or solicitation of any financial products or services. The content is not intended for residents of any jurisdiction where such distribution or use would be contrary to local law or regulation. Readers are advised to seek independent professional advice before making any investment or financial decisions. Any reliance you place on the information presented is strictly at your own risk. View original content to download multimedia: SOURCE Vantage Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
